Fluciclatide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125185

CAS#: 879894-00-5

Description: Fluciclatide is an integrin-targeted PET radiopharmaceutical.

Chemical Structure

img
Fluciclatide
CAS# 879894-00-5
Instruction

Theoretical Analysis

MedKoo Cat#: 125185
Name: Fluciclatide
CAS#: 879894-00-5
Chemical Formula: C75H115FN18O27S3
Exact Mass: 1,814.73
Molecular Weight: 1,816.020
Elemental Analysis: C, 49.60; H, 6.38; F, 1.05; N, 13.88; O, 23.79; S, 5.30

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fluciclatide; UQ6CV583Q3; AH-111585; UNII-UQ6CV583Q3; Fluciclatide F-18

IUPAC/Chemical Name: 2-((1R,4S,10R,13S,16R,19S,25S)-10-((1-amino-1,5-dioxo-3,9,12,15-tetraoxa-6-azaheptadecan-17-yl)carbamoyl)-13-benzyl-4-((E)-1-(4-fluorophenyl)-5,25,29-trioxo-3,9,12,15,18,21,27-heptaoxa-2,6,24,30-tetraazatetratriacont-1-en-34-yl)-25-(3-guanidinopropyl)-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octaazabicyclo[14.11.4]hentriacontan-19-yl)acetic acid

InChi Key: VXFFXZSNVKXXIB-SCSBXPEDSA-N

InChi Code: InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39+/t53-,54-,55-,56-,57-,58-,59-/m0/s1

SMILES Code: NC(COCC(NCCOCCOCCOCCNC([C@@H]1CSCC(N[C@H](C(N[C@H]2CSSC[C@@H](C(N[C@H](C(N1)=O)CC3=CC=CC=C3)=O)NC([C@@H](NC(CNC([C@@H](NC2=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)=O)CCCCNC(COCC(NCCOCCOCCOCCOCCOCCNC(CO/N=C/C4=CC=C(C=C4)F)=O)=O)=O)=O)=O)=O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,816.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mena E, Owenius R, Turkbey B, Sherry R, Bratslavsky G, Macholl S, Miller MP,
Somer EJ, Lindenberg L, Adler S, Shih J, Choyke P, Kurdziel K. [¹⁸F]fluciclatide
in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3
and α vβ 5 integrins. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1879-88. doi:
10.1007/s00259-014-2791-x. Epub 2014 Jun 28. PMID: 24973039; PMCID: PMC6336392.

2: Sharma R, Valls PO, Inglese M, Dubash S, Chen M, Gabra H, Montes A,
Challapalli A, Arshad M, Tharakan G, Chambers E, Cole T, Lozano-Kuehne JP,
Barwick TD, Aboagye EO. [18F]Fluciclatide PET as a biomarker of
response to combination therapy of pazopanib and paclitaxel in platinum-
resistant/refractory ovarian cancer. Eur J Nucl Med Mol Imaging. 2020
May;47(5):1239-1251. doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21. PMID:
31754793; PMCID: PMC7101300.

3: Tarkin JM, Mason JC, Fayad ZA. Imaging at the inter-face of inflammation and
angiogenesis by 18F-fluciclatide PET. Heart. 2019
Dec;105(24):1845-1847. doi: 10.1136/heartjnl-2019-315487. Epub 2019 Aug 30.
PMID: 31471464.

4: Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV,
Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR,
Aboagye EO. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in
Subjects with Solid Tumors. J Nucl Med. 2015 Dec;56(12):1855-61. doi:
10.2967/jnumed.115.158253. Epub 2015 Sep 17. PMID: 26383153.

5: Jenkins WS, Vesey AT, Vickers A, Neale A, Moles C, Connell M, Joshi NV,
Lucatelli C, Fletcher AM, Spratt JC, Mirsadraee S, van Beek EJ, Rudd JH, Newby
DE, Dweck MR. In vivo alpha-V beta-3 integrin expression in human aortic
atherosclerosis. Heart. 2019 Dec;105(24):1868-1875. doi:
10.1136/heartjnl-2019-315103. Epub 2019 Aug 17. PMID: 31422361; PMCID:
PMC6929706.